Compare Cytokinetics Inc (CYTK) vs Direxion Daily 20 Year Treasury Bull 3X Shares (TMF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Direxion Daily 20 Year Treasury Bull 3X Shares — how do they compare? Cytokinetics Inc trades at $81.61 (market cap $11.12B), while Direxion Daily 20 Year Treasury Bull 3X Shares trades at $33.12. The key difference: Cytokinetics Inc is trading nearer its 52-week high, Direxion Daily 20 Year Treasury Bull 3X Shares nearer its low. Which is the better fit depends on your goals.
| CYTK | TMF | |
|---|---|---|
Market Cap | $11.12B | — |
Sector | Technology | Leveraged / Inverse |
52-Week High | $87.26 | $44.14 |
52-Week Low | $33.23 | $31.85 |
Enterprise Value | $11.59B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $82.24, down 3.1% today, with a bullish technical outlook supported by moving averages and RSI near oversold levels. The company shows strong analyst support with 97% buy ratings and a $110.40 consensus target, but faces fundamental challenges with a -784% net income margin and negative cash flow from operations of -$510M in 2025. Recent positive developments include FDA approval and European launch of Myqorzo, driving commercial momentum.
Outlook remains speculative with high valuation (P/S 93.92) against significant losses, yet growth potential exists if Myqorzo gains market traction. Key risks include cash burn, competitive pressure, and reliance on single drug success. Institutional sentiment is overwhelmingly bullish, but investors must weigh high risk-reward profile amid ongoing profitability challenges.
TMF, a leveraged ETF tracking long-term US Treasuries, trades at $32.81, down 1.83% today. Technical indicators are bearish overall, with moving averages signaling strong selling pressure, though oscillators show some bullish momentum. The stock lacks traditional fundamental metrics like P/E or revenue due to its ETF structure, relying instead on underlying bond performance and interest rate trends.
Outlook remains volatile, driven by Federal Reserve policy shifts and bond market fluctuations. Risks include daily leverage decay and interest rate sensitivity. Analyst sentiment is mixed, with some seeing opportunity at bond market lows, while others caution against long-term holds due to amplified losses in rising rate environments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Direxion Daily 20 Year Treasury Bull 3X Shares
TMF is a leveraged ETF that seeks to provide 300% (3x) of the daily performance of the ICE U.S. Treasury 20+ Year Bond Index. It is a tactical instrument used by sophisticated traders to capitalize on declining interest rates or to hedge against equity market volatility. Due to its daily reset mechanism and high expense ratio, TMF is structurally designed for short-term speculation rather than long-term buy-and-hold investing.
Read more on TMF →
